Dexamethasone against yellow sub-threshold micropulse laser in the treatment of chronic central serous chorioretinopathy (DAYA) - Nil

Hyderabad Eye Research Foundation0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年6月26日

试验速览

暂无简介。

•1.Adults of both genders aged 30 years or more
•2.Diagnosis of cCSC confirmed at screening visit by complete ocular examination and multimodal imaging in the study eye
•3.Best corrected vision score of 73 to 19 at test distance of 4 meters on ETDRS chart at recruitment (Snellen equivalent 20/40 to 20/400)
•4.Decrease in vision primarily secondary to cCSC
•5.Willing to sign informed consent form before initiation of any study related procedure.

•1.Patients not able to comply with the study or follow up procedures
•2.Laser/ PDT treatment for CSC within 3 months of enrolment
•3.Use of corticosteroids in all forms within 3 months of enrolment
•4.Pharmacological treatment (eplerenone) for CSC within a month of enrolment
•5.Eyes with choroidal neovascularization demonstrable on multimodal imaging (OCTA/FA/ICGA)
•6.Non-study eye vision of <20/200,
•7.Aphakia in study eye
•8.History of glaucoma in either eye (IOP >24 mmHg)
•9.Cataract grade dense enough to affect retinal imaging
•10.History of hypersensitivity to fluorescein dye
•11.Presence of sub-retinal fluid (SRF) or intra-retinal fluid (IRF) secondary to causes other than CSC
•12.Presence of active infectious disease or intra-ocular inflammation, active or suspected periocular infection in either eye at the time of enrolment
•13.History of intra-ocular surgery within 3 months in the study eye prior to the randomization
•14.Pregnancy induced CSC.

发起方